|Articles|June 10, 2011
Podcast Interview: Chris Garabedian, CEO, AVI BioPharma
In our latest podcast, Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.
Advertisement
Interview: Chris Garabedian
Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Global Disruptions to the Pharma Supply Chain: Q&A with Jeff Golfman
2
Sanofi Officially Appoints Belén Garijo as Chief Executive Officer Following Shareholder Vote
3
How a Shifting Landscape is Making Affordable DTP At Scale a Reality
4
Pharmaceutical Risks in the Strait of Hormuz
5